Canakinumab or emavusertib for anemia in lower-risk MDS: results of the CANFIRE and LUCAS phase 2, open-label, multicenter trials. (PubMed, Commun Med (Lond)) - Sep 17, 2026 - P2 | "Inhibition of IL-1β or IRAK4 signaling with canakinumab or emavusertib did not result in hematologic improvement in patients with LR-MDS."
Journal • P2 data • Anemia • Hematological Disorders • Hematological Malignancies • Myelodysplastic Syndrome • Myeloproliferative Neoplasm • Oncology • IL1B • IRAK4
|
|
Anne Sophie Platzbecker; Aristoteles Giagounidis; Daniel Nowak; Daniel Sasca; Dirk Hasenclever; Dominic Brauer; Friederike Wortmann; Jens Przybilla; Karin Mayer; Katharina Götze; Katharina Zoldan; Kathrin Rieger; Katja Sockel; Klaus H Metzeler; Marie Schneider; Martin Schmidt-Hieber; Michael Cross; Philipp Kiewe; Rudolf Weide; Stefan Mahlmann; Susanne Melzer; Thomas Illmer; Ursula Vehling-Kaiser; Uwe Platzbecker
|